8 results match your criteria: "Bone Marrow Transplant Center (CEMO) of the Brazilian National Cancer Institute (INCA)[Affiliation]"
Int J Oncol
June 2021
Laboratory of Cellular and Molecular Hemato‑Oncology, Program of Molecular Hemato‑Oncology, Brazilian National Cancer Institute (INCA), Rio de Janeiro, RJ 20230‑130, Brazil.
Acute myeloid leukemia (AML) is a complex hematological disorder characterized by blockage of differentiation and high proliferation rates of myeloid progenitors. Anthracycline and cytarabine‑based therapy has remained the standard treatment for AML over the last four decades. Although this treatment strategy has increased survival rates, patients often develop resistance to these drugs.
View Article and Find Full Text PDFInt J Environ Res Public Health
July 2020
Technical Area of Environment, Work and Cancer, Prevention and Surveillance Coordination, National Cancer Institute José Alencar Gomes da Silva-INCA, Rio de Janeiro CEP 20230-240, Brazil.
In Brazil, gas station workers are occupationally exposed to the benzene present in gasoline. Brazilian law indicates the use of trans,trans-muconic acid(t,t-MA) as a biomarker of benzene exposure. The aim of this study was to evaluate the level of exposure to benzene in gas station workers, through the quantification of t,t-MA present in urine.
View Article and Find Full Text PDFStem Cell Res
December 2018
Laboratory of Molecular Biology, Bone Marrow Transplant Center (CEMO), Brazilian National Cancer Institute (INCA), Praça Cruz Vermelha, 23, Rio de Janeiro 20230-130, Brazil. Electronic address:
Primary myelofibrosis (PMF) is a hematological malignancy characterized by activation of the JAK/STAT pathway and risk of leukemic transformation. In this study, we generated an induced Pluripotent Stem (iPS) cell line derived from a 65-year old male PMF patient carrying the 5-pb insertion in the CALR gene (CALR) and the c.437 G > A mutation in the TP53 gene (p.
View Article and Find Full Text PDFBr J Haematol
May 2019
University Hospital, Rio de Janeiro, Federal University (UFRJ), Rio de Janeiro, Brazil.
Mol Cytogenet
July 2018
1Bone Marrow Transplatation Center (CEMO), National Cancer Institute (INCA), Rio de Janeiro, Brazil.
Background: Myelodysplastic syndrome (MDS) is rare in the pediatric age group and it may be associated with inheritable bone marrow failure (BMF) such as Fanconi anemia (FA). FA is a rare multi-system genetic disorder, characterized by congenital malformations and progressive BMF. Patients with FA usually present chromosomal aberrations when evolving to MDS or acute myeloid leukemia (AML).
View Article and Find Full Text PDFStem Cell Res
October 2017
Molecular Carcinogenesis Program, Research Coordination, Brazilian National Cancer Institute (INCA), Rua André Cavalcante 37, Rio de Janeiro 20230-240, Brazil; FIOCRUZ - Oswaldo Cruz Foundation Institute, Avenida Brasil 4365 - Manguinhos, Rio de Janeiro 21040-360, Brazil. Electronic address:
Peripheral blood sample was donated by a 61years old female patient diagnosed with acute myeloid leukemia secondary to a primary myelofibrosis harboring the 52-bp deletion in the CALR gene (c.1092_1143del, p.L367fs*46) and the R693X mutation in the ASXL1 gene (c.
View Article and Find Full Text PDFJ Med Case Rep
May 2017
Department of Surgery, Federal University of Ceará, Fortaleza, Ceara, Brazil.
Background: Myelodysplastic syndromes are heterogeneous disorders. Patients with myelodysplastic syndrome disease often have ineffective hematopoiesis, cytopenias, blood cell dysplasia in one or more cell types, and are at high risk for developing acute myeloid leukemia. In myelodysplastic syndrome, mutations of TP53 gene are usually associated with complex karyotype and confer a worse prognosis.
View Article and Find Full Text PDFSurg Oncol
September 2015
Bone Marrow Transplant Center (CEMO) of the Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil. Electronic address:
The implantation of Long-Term Central Venous Catheters (LTCVC) in cancer patients has been essential to conduct the oncological treatments of today. The complexity of the protocols requires accuracy on the management of such devices in order to keep them long-functioning. The article focuses on such subject from an oncological perspective, pointing out threats of the disease to the central venous system (CVS) and the ways to face them successfully.
View Article and Find Full Text PDF